CLYM116 shows deep, durable APRIL suppression; 12-week dosing supported
CLYM116, an anti-APRIL antibody for IgA nephropathy, showed deep and durable APRIL suppression and favorable safety in phase I, with reductions in IgA, Gd-IgA1 and IgM. PK/PD supports 12-week dosing; phase II and III planned.